254
Participants
Start Date
June 10, 2022
Primary Completion Date
November 30, 2023
Study Completion Date
March 31, 2025
SKB264
"SKB264 :5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
Cancer Hospital Chinese Academy of Medical Science, Beijing
Jiangsu Province Hospital, Nanjing
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
INDUSTRY